Listed by the USPTO as VAN BUREN, LAUREN K
Tech Center 1600 • Art Units: 1632 1638 1641 1651 1655
This examiner grants 40% of resolved cases
VAN BUREN, LAUREN K is assigned to Tech Center 1600 and Art Unit 1632. The profile includes 425 resolved cases and a 40.0% allowance rate. The median time to allowance is 1544 days, so applicants should incorporate a prolonged prosecution timeline into portfolio planning and decisions about claim scope, continuation filings, and commercial timing.
The interview lift is 58.4%, showing a substantial association between interviews and allowance outcomes in the recorded cases. Osiris Therapeutics Inc., Toray Industries Inc., and Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. are the listed companies. Norton Rose Fulbright US LLP, Morgan, Lewis & Bockius LLP (WA), and SUGHRUE MION, PLLC are the listed firms. The profile supports giving interview preparation meaningful strategic attention while maintaining strong written support.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18105204 | TISSUE-ENGINEERED INTERVERTEBRAL DISC WITH LIVING CELLS | Final Rejection | Cornell University |
| 18029354 | METHOD FOR CRYOPRESERVING A PLURALITY OF CELL CLUSTERS OF BIOLOGICAL CELLS | Final Rejection | Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V. |
| 16089918 | METHOD OF PRODUCING SUGAR LIQUID | Non-Final OA | Toray Industries, Inc. |
| 18558065 | STRING-LIKE AGGREGATES OF RETINAL PIGMENT EPITHELIAL CELLS, DEVICE AND PRODUCTION METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT COMPRISING SAID STRING-LIKE AGGREGATES | Non-Final OA | RIKEN |
| 18560000 | Methods and Compositions for Extending Organ and Tissue Preservation | Final Rejection | The General Hospital Corporation |
| 18689161 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS AND COMPOSITIONS THEREFOR | Non-Final OA | Yale University |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | Final Rejection | BioNTech SE |
| 18790185 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | Non-Final OA | Imvela Corp. |
| 18685860 | METHOD FOR CREATING FORMABLE CARTILAGE TISSUE WITHOUT REQUIRING SCAFFOLD | Final Rejection | Public University Corporation Yokohama City University |
| 18024012 | ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | Non-Final OA | Nkarta, Inc. |
| 18558215 | Delivery of Cellular Material and Other Material as a Dry Powder | Final Rejection | Pinata Holdings Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy40.0% of resolved applications examined by Lauren K Van Buren were allowed (425 resolved cases), compared with 38.0% across Art Unit 1632 over the last five years.
This examiner's interview lift is +58.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Lauren K Van Buren took 1,544 days on average from filing to allowance.
Lauren K Van Buren examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).